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Cystatin C and Long-Term Mortality Among
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Estimated Glomerular Filtration Rates
NHANES III (Third National Health and Nutrition Examination Survey)
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Man-Huei Chang, MPH, Juey-Jen Hwang, MD, PHD,*† Yu-Sheng Lin, SCD§
Dou-Liou City and Taipei, Taiwan; Fort Worth, Texas; and Atlanta, Georgia
Objectives The objective was to test the association of cystatin C (Cys-C) with long-term mortality risk in the subjects with
normal creatinine-based estimated glomerular filtration rates (eGFR).
Background Cys-C has been proposed as a sensitive indicator of renal dysfunction that is associated with cardiovascular
events. The predictive value of Cys-C for mortality risk (both cardiovascular and noncardiovascular) and its utility
among persons with normal kidney function remains unclear.
Methods The analysis included 2,990 subjects over 40 years of age with normal eGFR who participated in NHANES III (Third
National Health and Nutrition Examination Survey). Normal eGFR was defined by Modification of Diet in Renal Dis-
ease (MDRD) equation 60 ml/min/1.73 m2. Serum Cys-C was categorized as high, medium, or low. In 1 analysis,
the high and low groups were the top and bottom 10%, and in the second analysis, they were the upper and lower
thirds. All-cause and cause-specific mortality were obtained from the NHANES III–linked follow-up file through Decem-
ber 31, 2006. Multivariate Cox regression models were applied to assess the association of interest.
Results Within an average of 13.7 years follow-up, 488 cardiovascular and 719 noncardiovascular deaths occurred.
When the first and last deciles were compared, the relative risks were all increased statistically as follows: all-
cause, 4.36 (95% confidence interval [CI]: 2.52 to 7.82); cardiovascular, 7.44 (95% CI: 3.06 to 18.1); cancer,
2.45 (95% CI: 0.85 to 7.04); and noncardiovascular 3.15 (95% CI: 1.53 to 6.49) mortalities. Relative risks all
moderated to lower values when the comparisons were expanded to include the upper and lower thirds. Similar
associations were still present when Cys-C was modeled on a continuous scale, suggesting a linear relationship
between Cys-C and mortality outcomes.
Conclusions Serum Cys-C is prognostic of long-termmortality in the subjects with relatively normal renal function, independent of MDRD
eGFR and albuminuria. (J Am Coll Cardiol 2010;56:1930–6) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.04.069p
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fiystatin C (Cys-C) is a 13-kDa protein and member of the
amily of competitive lysosomal cysteine protease inhibitors.
he continual synthesis of Cys-C in nucleated cells and its
ssociation with pre-clinical renal disease have prompted
he use of Cys-C to estimate renal function. For instance,
igh serum Cys-C is reportedly predictive for all-cause
ortality, cardiovascular disease, and the prognosis for
ongestive heart failure (1,2).
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November 30, 2010:1930–6 Cystatin C and Long-Term Mortalityreatinine, the primary tool for evaluation of kidney func-
ion in clinical practice, can be affected by extrarenal factors
ncluding age, body weight, nutritional status, ethnicity, and
ender (4). In addition, it is insensitive to modest decreases
n kidney function (5). As a result, Cys-C has been
uggested as a more accurate estimate of GFR than
reatinine-based equations and may also predict declining
idney function even when the GFR is actually near the
ormal range (6).
Although renal dysfunction appears to be the most
lausible link between increased Cys-C and impaired car-
iovascular outcomes, the predictive value of Cys-C for
ong-term mortality outcomes among populations with
ormal kidney function has not been studied extensively (7).
n addition, whereas most studies on Cys-C focus on
ardiovascular outcomes, it remains unclear whether ele-
ated Cys-C is also associated with increased mortality of
ancer and other noncardiovascular disorders. In the current
tudy, cohort follow-up data were analyzed to test the
ypothesis that Cys-C is associated with long-term mortal-
ty for all-cause, cardiovascular disease, cancer, and noncar-
iovascular death among subjects with normal creatinine-
ased GFR. The data were obtained from a large national
ataset.
ethods
tudy design and population. NHANES III (Third Na-
ional Health and Nutrition Examination Survey) was
onducted by the National Center for Health Statistics
NCHS) from 1988 to 1994 using a stratified, multistage,
nd cluster sampling design to obtain a representative
ample of the noninstitutionalized civilian U.S. population.
he NHANES III was reviewed and approved by the
CHS Institutional Review Board. Data collection in-
luded in-depth, in-person interviews, physical and physi-
logical examinations, and laboratory tests. This study was
estricted to 2,990 non-Hispanic Whites, non-Hispanic
lacks, and Mexican-American participants aged 40 years
r older with normal kidney function, defined as Modifica-
ion of Diet in Renal Disease (MDRD) estimated glomer-
lar filtration rate (eGFR) 60 ml/min/1.73 m2, and valid
easurements of serum Cys-C (8). Serum Cys-C was
easured in NHANES III in all participants age 60 years
nd in a 25% random sample of participants age 12 to 59
ears. A sample weight variable for Cys-C was thus used to
djust for the unequal probabilities of selection to represent
he U.S. population (9).
easurements of serum Cys-C. Serum from fasting
lood samples was stored at 70°C until analyzed. Cys-C
as then measured using a particle-enhanced immunoneph-
lometric assay (N Latex Cys-C, Dade Behring, Deerfield,
llinois) at the Cleveland Clinical Research Laboratory.
ys-C samples with this assay had a range of 0.23 to 7.25
g/l (17.2 to 543.0 nmol/l) and an intra-assay imprecision df 2.0% to 3.0% coefficient of
ariation and an interassay im-
recision of 3.2% to 4.4% coeffi-
ient of variation (10).
aseline demographic and clinical
actors. Data were collected by
rained personnel according to
tandardized procedures (11).
nformation for age, sex, and
moking was self-reported. Cur-
ent cigarette smoking was coded
s a dichotomous “yes/no” vari-
ble. Hypertension was defined
s an average systolic blood pres-
ure 140 mm Hg, a diastolic
lood pressure 90 mm Hg, a
hysician’s diagnosis or the use of antihypertensive medica-
ion (12). Diabetes mellitus was assessed by self-reported
iagnosis of diabetes, the use of diabetic medications (insu-
in or oral agents), a nonfasting plasma glucose 11.1
mol/l (200 mg/dl), or a fasting plasma glucose7 mmol/l
126 mg/dl). Serum triglycerides, high-density lipoprotein
holesterol, low-density lipoprotein cholesterol, fibrinogen,
ric acid, hemoglobin, blood urea nitrogen, C-reactive
rotein (CRP), urinary albumin, and creatinine were ana-
yzed by laboratory methods reported elsewhere (13). Uri-
ary albumin-to-creatinine ratios (UACR, in mg/mmol)
ere calculated accordingly (14,15). The GFR was calcu-
ated from MDRD (Modification of Diet in Renal Disease)
tudy equation: (ml/min/1.73 m2)  175  (Scr)1.154 
Age)0.203  (0.742 if female)  (1.210 if African Amer-
can) (16). Serum creatinine was measured by means of the
odified kinetic Jaffé reaction, followed by calibration
sing an enzymatic creatinine assay traceable to a gold-
tandard reference method as described previously (17).
ortality follow-up. The underlying cause of death was
oded using the International Classification of Diseases-
0th Revision (ICD-10) (18). The association of Cys-C
ith long-term mortality was evaluated for deaths from
ll-cause, cardiovascular disease (ICD codes: I00 to I78),
alignant neoplasm (ICD-10 codes: C00 to C97), and
oncardiovascular mortality. Noncardiovascular mortality
as defined as mortality cases not belonging to the category
f cardiovascular causes. Length of follow-up for each
articipant was calculated as the time from the NHANES
II examination date to the end of follow-up (date of death
r December 31, 2006). Thus, those found alive were
ight-censored on the last date known alive or at the end of
he study, and likewise those who died from other causes
ere also right-censored at the time of death for cause-
pecific analysis. Age-adjusted all-cause and cause-specific
ortality rates (per 1,000 person-years) were calculated
sing direct standardization according to the 2000 U.S.
tandard population (19).
tatistical analysis. NHANES used a complex sampling
Abbreviations
and Acronyms
AUC  area under
the curve
Cys-C  cystatin C
eGFR  estimated
glomerular filtration rate
GFR  glomerular filtration
rate
ROC  receiver-operating
characteristic
TG  triglyceride
UACR  urinary
albumin-to-creatinine ratioesign and a complex survey design, including nonresponse
a
w
(
N
t
m
i
a
t
g
(
t
(
t
T
p
m
m
h
s
t
C
b
p
r
u
c
c
a
w
(
d
r
R
B
T
a
y
m
0
m
s
t
g
0
d
a
t
O
m
i
t
b
(
1
t
1932 Wu et al. JACC Vol. 56, No. 23, 2010
Cystatin C and Long-Term Mortality November 30, 2010:1930–6nd unequal sampling probabilities, and provided sampling
eights for constructing national estimates. SUDAAN 9.03
2004, Research Triangle Institute, Research Triangle Park,
orth Carolina) was used with the Taylor-series lineariza-
ion to obtain unbiased standard errors for statistical esti-
ates in all analyses. Demographic and clinical character-
stics were compared across 3 categories of Cys-C level with
nalysis of variance (ANOVA) for continuous variables and
he Cochran-Mantel-Haenszel chi-square test for cate-
orical variables. Subjects were classified into the high
90th percentile) (Cys-C 1.08 mg/l), medium (10th
o 90th percentile) (Cys-C 0.7 to 1.08 mg/l), and low
10th percentile) (Cys-C 0.7 mg/l) and also into
ertiles (Cys-C 0.80, 0.80 to 0.93, and 0.93 mg/l).
ime to event was first examined using the Kaplan-Meier
roduct limit survival method, followed by univariate and
ultivariate Cox proportional hazard model with Efron
ethod to calculate relative risk (RR), also known as the
azard ratios, to evaluate mortality risk associated with
erum Cys-C for all-cause and cause-specific deaths. Po-
ential confounding factors such as MDRD, UACR, and
RP were accordingly examined and adjusted in the models
ased on p values from univariate analyses (included when
 0.10) and prior knowledge regarding the importance of
isk factors. The level of significance was set at 0.05.
The receiver-operating characteristic (ROC) curves were
sed to assess the discriminative power of Cys-C as a
ontinuous variable to differentiate the occurrence of all-
ause mortality, cardiovascular mortality, cancer mortality,
nd noncardiovascular mortality. Area under curve (AUC)
Baseline Demographic and Clinical CharacteristTable 1 Baseline Demographic and Clinical
Characteristics
<10th Percentile
(<0.70 mg/l)
(n  214)
Males, %* 20.6 (5.02)
Microalbuminuria, % 12.2 (4.41)
Diabetes, % 14.7 (4.31)
Hypertension, % 25.0 (4.39)
Current smoking, % 20.4 (4.09)
Age, yrs 46.8 (0.73)
BMI, kg/m2 25.0 (0.62)
Hemoglobin, g/dl 13.5 (0.19)
TG, mg/dl 117.7 (10.5)
HDL, mg/dl 58.5 (2.38)
Fibrinogen, mg/dl 310.1 (13.5)
C-reactive protein, mg/l 0.35 (0.03)
Uric acid, mg/dl 4.16 (0.13)
Fasting glucose, mg/dl 113.3 (8.09)
Blood urea nitrogen, mg/dl 12.3 (0.37)
Serum creatinine, mg/dl 0.92 (0.01)
eGFR, ml/min/1.73 m2 79.4 (1.40)
UACR, mg/mmol 4.85 (2.59)
All demographic and clinical variables, except fasting glucose, are stat
as either mean or percentage with standard error. *With adjustmenteGFR  glomerular filtration rate calculated from the Modification of D
lipoprotein; LDL  low-density lipoprotein; TG  triglyceride; UACR  urinaryas calculated. The optimal cutoff point, defined as the least
1  sensitivity)2  (1  specificity)2 or the shortest
istance from the left upper corner to the ROC curve, was
eported.
esults
aseline demographic and clinical variables are shown in
able 1. The sample of 2,990 participants was equivalent to
n estimated U.S. population of 63,192,373 persons 40
ears of age after adjusting for sample weights. The overall
ean ( SE) serum Cys-C of the study population was
.89  0.01 mg/l (5th to 95th percentile range 0.66 to 1.16
g/l), with the average concentrations, respectively, for
ubjects in the high (highest decile, n  577), medium (2nd
o 9th decile, n  2,199), and low (lowest decile, n  214)
roups were 1.19  0.008 mg/l, 0.87  0.004 mg/l, and
.65  0.005 mg/l (Fig. 1). Except fasting glucose, all
emographic and clinical variables were statistically different
cross Cys-C categories (p 0.05, ANOVA and chi-square
ests for continuous and categorical outcomes, respectively).
verall, the participants in the high Cys-C group were
ore often older, male, and hypertensive. Likewise, CRP
ncreased with Cys-C concentrations (Spearman’s correla-
ion: 0.092, p  0.001). In addition, there was a significant
ut nonlinear relationship between Cys-C and UACR
Spearman’s correlation: 0.164, p 0.001, data not shown).
Within an average of 13.7 years of follow-up (range 0.5 to
8 years), 1,206, 487, 320, and 719 subjects died, respec-
ively, from all-cause, cardiovascular, cancer, and noncar-
f Participants* (n  2,990)acteristics of Participants* (n  2,990)
Cystatin C
10th–90th Percentile
(0.70–1.08 mg/l)
(n  2,199)
>90th Percentile
(>1.08 mg/l)
(n  577)
53.3 (1.96) 62.1 (3.82)
10.6 (1.15) 22.3 (2.94)
6.77 (1.19) 11.3 (1.97)
39.9 (1.69) 51.9 (3.54)
24.8 (1.84) 35.5 (4.70)
53.4 (0.56) 64.3 (1.17)
27.4 (0.19) 28.0 (0.28)
14.3 (0.07) 14.3 (0.07)
170.0 (10.7) 184.8 (9.52)
50.0 (0.79) 44.9 (0.99)
295.5 (4.34) 322.8 (7.57)
0.42 (0.03) 0.62 (0.06)
5.35 (0.06) 5.91 (0.09)
101.6 (1.90) 103.9 (2.83)
14.2 (0.22) 16.0 (0.35)
1.03 (0.01) 1.08 (0.01)
73.5 (0.38) 68.6 (0.61)
1.77 (0.20) 7.62 (3.29)
different across cystatin C categories (p 0.05). Data are expressed
ple weight.ics oChar
istically
for samiet in Renal Disease (MDRD) study equation; HDL  high-density
albumin-to creatinine ratio.
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November 30, 2010:1930–6 Cystatin C and Long-Term Mortalityiovascular causes. This corresponds to age-adjusted mor-
ality rates (year 2000 U.S. standard population) of 19.8,
.7, 5.7, and 12.1 per 1,000 person-years in that order (data
ot shown). The results from Kaplan-Meier survival curves
tratified by Cys-C categories for all-cause (Fig. 2A) and
ause-specific mortality (Figs. 2B to 2D) showed that, when
ompared with persons with low Cys-C, those with me-
ium or high levels of Cys-C concentrations were generally
t higher risk for all-cause and cause-specific mortality.
imilar results were obtained from univariate analyses
Table 2). For instance, the relative risks for all-cause
ortality for high and medium Cys-C were 17.6 (95% CI:
0.1 to 30.9) and 5.64 (95% CI: 3.11 to 10.2), respectively,
s compared with those with low levels of serum Cys-C.
espite the decrease in relative risks following adjustment
or age, sex, diabetes mellitus, hypertension, smoking, CRP,
ACR, and MDRD eGFR, the associations between
ys-C and mortality risk remained significant for all-cause,
ardiovascular, and noncardiovascular disease but not for
ancer (Table 2). Although an apparent increased risk of
ancer mortality was still observed in individuals with high
nd medium Cys-C, the results did not attain statistical
ignificance (p  0.18). Similar trends were observed when
he population was divided into tertiles based on serum
ys-C concentrations. The associations were statistically
ignificant for all-cause and cause-specific mortalities in the
nivariate analyses but did not reach statistical significance
fter adjustment for covariates (Online Table 1).
Of the covariates examined in multivariate-adjusted anal-
Figure 1 Histogram of Serum Cys-C Concentrations
The histogram shows the distribution of serum cystatin C (Cys-C) concentrations.
Kolmogorov-Smirnov Z-test indicates a deviation from normal distribution (p 
0.001). The overall mean ( SE) serum Cys-C of the study population was 0.89 
0.01 mg/l (5th to 95th percentile range: 0.66 to 1.16 mg/l). Solid curve  the
normality plot.ses, age and current smoking were 2 leading risk factors for eortality. Excluding cancer, MDRD eGFR and UACR
ere important predictors of all-cause and cause-specific
eaths (p  0.05). Hypertension and CRP are likewise
elated to increased mortality risk, but are only significant in
ll-cause mortality and cancer death (hypertension only).
ex and diabetes were also significantly associated with
ll-cause and cardiovascular mortality (p  0.05) (Table 2,
nline Table 1).
The multivariate-adjusted relative risks by modeling mor-
ality using log-transformed serum Cys-C concentrations
n a continuous scale were significant for all-cause, 3.96
95% CI: 2.17 to 7.23, p  0.001), cardiovascular disease,
.51 (95% CI: 1.96 to 21.6, p  0.003), noncardiovascular
isease, 2.77 (95% CI: 1.14 to 6.71, p  0.03) but not for
ancer, 2.26 (95% CI: 0.57 to 9.04, p  0.24) (data not
hown). The comparable findings suggested a dose-responsive
elationship between Cys-C and mortality outcomes. ROC
nalysis showed that the AUC for all-cause mortality, cardio-
ascular mortality, cancer mortality, and noncardiovascular
ortality were 0.72, 0.74, 0.64, and 0.67, respectively. The
stimated optimal cutoff values of Cys-C were 0.95 mg/l for
ll-cause and cardiovascular mortality and 0.97 mg/l for cancer
nd noncardiovascular mortality (Online Fig. 1).
iscussion
he present study demonstrates that an elevated serum
ys-C concentration is associated with all-cause, cardiovas-
ular, and noncardiovascular mortality adjusted for other
isk factors (e.g., MDRD eGFR and albuminuria) in a
eneral population with creatinine-based eGFR 60 ml/
in/1.73 m2. In general, the results support previous
ndings suggesting that Cys-C is linked to long-term
ll-cause and cardiovascular mortality independent of kid-
ey function (20).
Although the mechanisms through which elevated
ys-C relates to long-term mortality remain undeter-
ined, it is generally assumed that serum Cys-C reflects
he balance of its primary physiological determinants:
ellular generation, renal filtration, and subsequent renal
egradation (9). Also, the generation of Cys-C by nucle-
ted cells is constant, and the concentration is not
nfluenced by age, sex, height, and body composition
21). An increased Cys-C concentration identifies early
eviations in GFR and becomes a sensitive indicator of
pre-clinical” renal disease, which thus may be associated
ith adverse cardiovascular outcomes (6). In addition,
nflammatory status, thyroid disease, serum CRP, and
urrent smoking were all associated with Cys-C concen-
rations (22). Inflammatory cytokines associated with
therosclerosis may alter the relationship between lyso-
omal cathepsins and their endogenous inhibitors like
ys-C in favor of remodeling and atherogenesis (23).
lastolytic cysteine proteases and their inhibitors, includ-
ng Cys-C, are suggested to be involved in the pathogen-
sis of atherosclerosis (24). This may explain in part the
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Cystatin C and Long-Term Mortality November 30, 2010:1930–6echanism underlying the statistical link between Cys-C
nd cardiovascular outcomes in subjects with normal
reatinine-based eGFR. Thus, increases in serum Cys-C
ay be sensitive harbingers of cardiovascular disease that
re associated with inflammation (e.g., CRP) and ath-
rosclerosis (25). Alternatively, the connection may be
elated to other pathophysiologic pathways that amplify
Figure 2 Survival Curves for All-Cause and Cause-Specific Mort
Kaplan-Meier cumulative survival curves for risk for (A) all-cause, (B) cardiovascul
cystatin C (Cys-C) levels: high, 90th percentile; medium, 10th to 90th percentile; lowhe mortality risk independent of GFR (26). cPrevious studies have demonstrated that Cys-C pre-
icts all-cause mortality and cardiovascular events among
lderly cohorts, subjects with chronic kidney disease, or
atients with coronary heart disease (1,27,28). A recent
tudy on 4,663 elderly persons (age 65 years) by Shlipak
t al. (27) reported that higher Cys-C was associated with
igher risk for cardiovascular events and mortality. The
ase, (C) cancer, and (D) noncardiovascular cause stratified by
th percentile. x-axis indicates time (in years), y-axis indicates cumulative survival (%).ality
ar dise
, 10urrent study reinforces the prior findings that Cys-C is
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November 30, 2010:1930–6 Cystatin C and Long-Term Mortalityssociated with increased risk of all-cause and cardiovas-
ular mortality among the elderly, and expands these
ndings to include noncardiovascular disorders in a
ounger (age 40 years) population with average age of
3 years and “clinically normal” kidney function. The
OC analysis by Astor et al. showed that Cys-C– based
GFR was predictive of all-cause and cardiovascular
ortality, with an AUC of 0.80, in the general U.S.
opulation with creatinine-based eGFR 15 ml/min/
.73 m2 (29). In the current study, we used a simple
ichotomized approach to assess the mortality risk asso-
iated with serum Cys-C concentrations and found that
ys-C could still predict increased mortality in the
ubjects with normal creatinine-based eGFR who were
reviously thought to belong to a low-risk group.
Increased risk of noncardiovascular illness may reflect
ssociations between Cys-C and declining physical function
ediated by inflammation (30). Such subjects with declin-
ng health might reasonably have additional comorbidities,
uch as aspiration pneumonia and bedsore, and therefore are
rone to noncardiovascular mortality. Alternatively, high
ys-C may contribute to noncardiovascular mortality risks
ndirectly through cognitive impairments mediated by Cys-
–associated vascular disease (31).
tudy limitations. There are some limitations in the
urrent study. First, the selection of subjects used eGFRs
ased on single creatinine determinations. This potential
oncern is mitigated in part by the observation that
epeated creatinine measurements in a subpopulation of
,919 NHANES III subjects showed a reasonable agree-
ent between the 2 measurements (32). Thus, errors in
R of All-Cause and Cause-Specific Mortality by 10th to 90th Percys-C Levels and Other Confounding Risk FactorsTable 2 RR of All-Cause and Cause-Specific Mortality by 10th tCys-C Levels and Other Confounding Risk Factors
Predictor Variable
All-Cause Cardio
RR (95% CI) p Value RR (95% CI
Univariate analysis
Serum Cys-C level 0.001
90th percentile 17.6 (10.1–30.9) 24.9 (11.2–55
10th–90th percentile 5.64 (3.11–10.2) 5.98 (2.68–13
10th percentile 1.00 (reference) 1.00 (referenc
Multivariate analysis
Serum Cys-C level 0.001
90th percentile 4.36 (2.52–7.82) 7.44 (3.06–18
10th–90th percentile 3.45 (2.04–5.82) 4.59 (1.99–10
10th percentile 1.00 (reference) 1.00 (referenc
Males 1.41 (1.06–1.89) 0.02 1.67 (1.11–2.5
Diabetes, yes 1.35 (1.03–1.76) 0.03 1.72 (1.23–2.4
Hypertension, yes 1.36 (1.04–1.78) 0.03 1.38 (0.96–1.9
Current smoking, yes 2.00 (1.54–2.58) 0.001 1.79 (1.19–2.7
CRP, mg/l* 1.13 (1.00–1.28) 0.04 1.12 (0.90–1.3
UACR ratio, mg/mmol* 1.17 (1.10–1.25) 0.001 1.21 (1.08–1.3
Age, per yr 1.10 (1.09–1.11) 0.001 1.11 (1.09–1.1
eGFR, ml/min/1.73 m2* 4.25 (1.76–10.3) 0.002 9.51 (2.26–40
Log-transformed.
CI  confidence interval; CRP  C-reactive protein; Cys-C  cystatin C; RR  relative risk; otheelection of subjects as “normal” seem unlikely to account Eor the better prognostic value of Cys-C. On the other
and, it is not unlikely that the association of interest
ould be confounded by other risk factors, such as thyroid
isease, which may affect both Cys-C concentrations and
ortality outcomes (33). Also, several single nucleotide
olymorphisms have been associated with altered Cys-C
oncentrations (34). The current study, however, does
upport Cys-C concentrations as an indicator of in-
reased risk of long-term mortality independent of resid-
al renal function. Furthermore, a recent study showed
hat Cys-C was associated with an increased risk in the
omposite end point of death or rehospitalization in
atients hospitalized for heart failure (35). However, the
resent analysis dealt with long-term survival. Thus, the
ssociation between Cys-C and the incidence of nonfatal
ardiovascular events may have been missed.
onclusions
his study has demonstrated that Cys-C, an alternative
redictor of renal function, is significantly associated with
ll-cause, cardiovascular, and even noncardiovascular mor-
ality in the general population with normal kidney func-
ion. Thus, Cys-C has a unique prognostic potential regard-
ng long-term mortality. It remains to be elucidated as to
hether some novel combination of measurements will
rovide even greater sensitivity and predictive power includ-
ng perhaps for cancer.
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